Kim-Son Nguyen, M.D., MPA
Investigator
Dr. Kim-Son H Nguyen is a medical oncologist and Medical Director of the Department of Hematology-Oncology at Palo Alto Medical Foundation, Sutter Health. He leads a multidisciplinary oncology program serving multiple sites across the San Francisco Bay Area and has played a key role in developing advanced cancer care services in Santa Clara.
Dr. Nguyen earned his Doctor of Medicine from Harvard Medical School and a Master of Public Administration from the Harvard Kennedy School, with a focus on health policy, leadership, and analytics. He completed his internal medicine residency at Beth Israel Deaconess Medical Center and a hematology-oncology fellowship at Stanford University.
His clinical and research interests center on lung cancer, targeted therapies, and cancer care delivery. He serves as a principal investigator and co-investigator on multiple clinical trials. Dr. Nguyen is also deeply engaged in global oncology, having led international educational initiatives and founded the Vietnam Oncology Journal Club to advance cancer care education.
Clinical trials
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Status: Open to Enrollment
- Clinical trial
Metastatic 1st Line Non-Small Cell Lung Cancer HARMONi-7
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
Status: Open to Enrollment
- Clinical trial
Metastatic Colorectal Cancer C6461003
AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
Status: Open to Enrollment
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
Status: Open to Enrollment